Patterns of Quetiapine Use in Psychiatric Inpatients: An Examination of Off-Label Use

References

• Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indication for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry. 2004;3(4):1–10.
   Google Scholar
• Brooke NS, Wiersgalls M, Salzman C. Atypical uses of atypical antipsychotics. Harvard Rev of Psychiatry. 2005;13 :317–339.
   PubMed Web of Science ®Google Scholar
• Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker W. Off-label use of antipsychotic drugs. J Clin Psychopharmacol. 2000; (6):695–698.
   Google Scholar
• Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nation-ally in the department of veterans affairs. Med Care. 2001; 39(3):302–308.
   Google Scholar
• Goodnick PJ. Higher than physician desk reference (US) doses on atypical antipsychotics. Expert Opin Drug Saf 2005; 4(4):653–668.
   PubMedGoogle Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl. Practice guidelines for the treatment of patients with schizophrenia. In: American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. 2nd ed. Arlington, VA: American Psychi-atric Press;2004;249–441.
   Google Scholar
• FDA approval letter for quetiapine for major depressive episodes of bipolar disorder. Retrieved 01/07 from http://www.accessdata. fda.gov/
   Google Scholar
• Martin, A, Koenig, K, Scahill, L. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9:999–1007.
   Google Scholar
• Schutter SJ, Van Megen HJGM, Westenberg HGM. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psych. 2005;66(4):540–542.
   Google Scholar
• Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of que-tiapine in the treatment of borderline personality disorder. J Clin Psych. 2006;67:1042–1046.
   Google Scholar
• McConville, BJ, Arvanitis, LA, Thyrum, PT. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psych. 2000;61:252–260.
   Google Scholar
• DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM. A double blind random-ized pilot study comparing quetiapine and divalproex for adoles-cent mania. J Am Acad Child Adolesc Psychiatry. 2003; 45(3):305–313.
   Google Scholar
• Goldberg, RJ. Managing psychosis-related behavioral problems in the elderly. Consult Pharm. 1997;12(Suppl C):4–10.
   Google Scholar
• Yargic LI, Corapcioglu A, Kocabasoglu N. A prospective ran-domized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int .1 Psych Clin Pract. 2004; 8(4):205–211.
   Google Scholar
• Hirschfeld R, Weisler R, Raines S, McFadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double blind, placebo-controlled study. J Clin Psych. 2006;67:355–362.
   Google Scholar
• Denys D, De Geus F, Van Megen HJGM, Westenberg HGM. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psych. 2004;65(8):1040–1048.
   Google Scholar
• Boettger S, Breitbart W. Atypical antipsychotics in the manage-ment of delirium: a review of the empiric literature. Palliat Sup-portCare. 2005;3(3):227–37.
   Google Scholar
• Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. Rev Psychiatr Neurosci. 2004;29(6):452–457.
   Google Scholar
• Seeman S: Atypical antipsychotics. Mechanism of action. Can J Psychiatry. 2002;47:27–38.
   PubMed Web of Science ®Google Scholar
• Lieberman, JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis C, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Allison, DB, Mentore JL, Heo M,Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain. a comprehensive research synthesis. Am J Psychiatry. 1999; 156:1686–1696.
   Google Scholar
• Jones AM, Rak IW, Raniwalla J, Phung D, Melvin R. Weight changes in patients treated with Seroquel (quetiapine). Presented at the 38th annual meeting of the American College of Neuropsychopharmacology; Dec 12–16, 1999; Acapulco, Mexico.
   Google Scholar
• IMS Health, National prescriptions audit. Sponsored by Astra Zeneca. Retrieved 8/06 from http://www.seroquel.com
   Google Scholar
• Quetiapine package insert, AstraZeneca Pharmaceuticals LP. Wilmington, DE; 2005.
   Google Scholar
• Citrome L, Jaffe A, Levine J, Lindenmayer JP. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psych. 2005;66(12):1512–1516.
   Google Scholar
• Yatham LN. Diagnosis and management of patients with bipolar II disorder. J Clin Psych. 2005;66(1):13–17.
   Google Scholar
• Berk M, Dodd S. Bipolar II disorder: a review. Bipolar Disord. 2005;7(1):11–21.
   Google Scholar
• Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blnd, placebo controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7):1351–1360.
   PubMed Web of Science ®Google Scholar
• Chen, H, Reeves, JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psych. 2006;67:972–982.
   Google Scholar
• Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J. A post hoc analysis of the impact on hostility and agitation of que-tiapine and haloperidol among patients with schizophrenia. Clin Ther. 2003 ;25(2): 530–541.
   Google Scholar
• Sokolski KN, Brown BJ. Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. Ann Pharmaco-ther. 2006;40(3):567–570.
   Google Scholar
• Pinta ER, Taylor RE. Quetiapine addiction? (letter) Am J Psychia-try. 2007;164(1):174.
   PubMed Web of Science ®Google Scholar
• Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ("q-ball") (letter). Am J Psychiatry. 2007;164(1)173–174.
   Google Scholar
• Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse (letter). Am J Psychiatry. 2005;162:1755–1756.
   PubMed Web of Science ®Google Scholar
• Pierre JM, Shnayder I, Wirshing DA, Wirshing WC. Intranasal quetiapine abuse (letter). Am J Psychiatry. 2004;161:1718.
   PubMed Web of Science ®Google Scholar
• Del Paggio D. Psychotropic medication abuse in correctional facil-ities. The Bay Area Psychopharmacology Newsletter. 2005;8:1.
   Google Scholar